KR102714060B1 - 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 - Google Patents

리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 Download PDF

Info

Publication number
KR102714060B1
KR102714060B1 KR1020187005220A KR20187005220A KR102714060B1 KR 102714060 B1 KR102714060 B1 KR 102714060B1 KR 1020187005220 A KR1020187005220 A KR 1020187005220A KR 20187005220 A KR20187005220 A KR 20187005220A KR 102714060 B1 KR102714060 B1 KR 102714060B1
Authority
KR
South Korea
Prior art keywords
oxaliplatin
irinotecan
leucovorin
liposomal irinotecan
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187005220A
Other languages
English (en)
Korean (ko)
Other versions
KR20180039087A (ko
Inventor
사라 에프 블랑쳇
조나단 바질 피츠제랄드
다니엘 에프 가디
바트 에스 헨드릭스
애쉬쉬 칼라
헬렌 리
앨리엘 베이에버
Original Assignee
입센 바이오팜 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58100730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102714060(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 입센 바이오팜 리미티드 filed Critical 입센 바이오팜 리미티드
Publication of KR20180039087A publication Critical patent/KR20180039087A/ko
Application granted granted Critical
Publication of KR102714060B1 publication Critical patent/KR102714060B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020187005220A 2015-08-21 2016-08-19 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 Active KR102714060B1 (ko)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201562208209P 2015-08-21 2015-08-21
US62/208,209 2015-08-21
US201562216736P 2015-09-10 2015-09-10
US62/216,736 2015-09-10
US201562273244P 2015-12-30 2015-12-30
US62/273,244 2015-12-30
US201662281473P 2016-01-21 2016-01-21
US62/281,473 2016-01-21
US201662302341P 2016-03-02 2016-03-02
US62/302,341 2016-03-02
US201662323245P 2016-04-15 2016-04-15
US62/323,245 2016-04-15
US201662343313P 2016-05-31 2016-05-31
US62/343,313 2016-05-31
PCT/US2016/047727 WO2017034957A1 (en) 2015-08-21 2016-08-19 Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin

Publications (2)

Publication Number Publication Date
KR20180039087A KR20180039087A (ko) 2018-04-17
KR102714060B1 true KR102714060B1 (ko) 2024-10-08

Family

ID=58100730

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187005220A Active KR102714060B1 (ko) 2015-08-21 2016-08-19 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법

Country Status (17)

Country Link
US (5) US20170049775A1 (cg-RX-API-DMAC7.html)
EP (2) EP3791876A1 (cg-RX-API-DMAC7.html)
JP (3) JP2018528185A (cg-RX-API-DMAC7.html)
KR (1) KR102714060B1 (cg-RX-API-DMAC7.html)
CN (1) CN108495629A (cg-RX-API-DMAC7.html)
AU (1) AU2016310476B8 (cg-RX-API-DMAC7.html)
BR (1) BR112018002941B1 (cg-RX-API-DMAC7.html)
ES (1) ES2826826T3 (cg-RX-API-DMAC7.html)
HK (1) HK1257220A1 (cg-RX-API-DMAC7.html)
IL (1) IL257149B2 (cg-RX-API-DMAC7.html)
MX (1) MX385425B (cg-RX-API-DMAC7.html)
PT (1) PT3337478T (cg-RX-API-DMAC7.html)
RU (1) RU2747124C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201913077QA (cg-RX-API-DMAC7.html)
SI (1) SI3337478T1 (cg-RX-API-DMAC7.html)
TW (5) TWI778942B (cg-RX-API-DMAC7.html)
WO (1) WO2017034957A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2015360761B2 (en) * 2014-12-09 2021-05-20 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
AU2016309002B2 (en) 2015-08-20 2021-07-29 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment
HK1257220A1 (zh) * 2015-08-21 2019-10-18 益普生生物制药有限公司 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法
RS67289B1 (sr) 2015-10-16 2025-11-28 Ipsen Biopharm Ltd Stabilizacija farmaceutskih kompozicija kamptotecina
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
IL282317B2 (en) * 2018-10-17 2024-04-01 Biolinerx Ltd Treatment of metastatic pancreatic adenocarcinoma
EP3911353A1 (en) * 2019-01-17 2021-11-24 BioLineRx Ltd. Specific combination therapy for treatment of pancreatic cancer
WO2020148744A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
EP3988085A1 (en) * 2019-02-22 2022-04-27 Novocure GmbH Treating gastric cancer using ttfields and drug in combination
CA3157379A1 (en) * 2019-10-10 2021-04-15 The University Of North Carolina At Chapel Hill Delivery system complexes comprising a precipitate of an active agent and methods of use
WO2022266357A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napox
WO2022266354A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napoli

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
AU4990397A (en) 1996-10-22 1998-05-15 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
BR9914601A (pt) 1998-09-16 2001-10-23 Alza Corp Inibidor de topoisomerase capturado por lipossoma
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
DE60123583T2 (de) 2000-02-04 2007-08-09 Lipoxen Technologies Ltd. Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AU6147301A (en) 2000-05-15 2001-11-26 Celgene Corp Compositions and methods for the treatment of colorectal cancer
DE60115044T2 (de) 2000-06-30 2006-08-03 Inex Pharmaceuticals Corp., Burnaby Liposomale antineoplastische arzneimittel und deren verwendungen
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
NZ528523A (en) 2001-03-26 2006-03-31 Alza Corp Liposome composition for improved intracellular delivery of a therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
EP1408975A2 (en) 2001-07-23 2004-04-21 Epidauros Biotechnologie AG Methods for the treatment of cancer with irinotecan based on cyp3a5
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
EP1509203B1 (en) 2002-05-15 2016-04-13 California Pacific Medical Center Delivery of nucleic acid-like compounds
DE60331458D1 (de) 2002-05-31 2010-04-08 Transmolecular Inc Kombinationschemotherapie mit chlorotoxin
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
RS20160203A1 (sr) 2003-05-30 2016-10-31 Genentech Inc Tretman sa anti-vegf antitelima
KR101462819B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
AU2005249314B2 (en) 2004-06-01 2008-09-11 Kabushiki Kaisha Yakult Honsha Irinotecan preparation
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CA2628015C (en) 2005-10-25 2016-02-23 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
WO2007076117A2 (en) 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
JP5289060B2 (ja) 2006-01-17 2013-09-11 アボット・ラボラトリーズ Ｐａｒｐインヒビターとの組合せ療法
CA2647297A1 (en) 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
US20120003294A1 (en) 2007-08-17 2012-01-05 Celator Pharmaceuticals, Inc. Fixed ratio camptothecens/platinum agents
EP2197917A1 (en) 2007-09-28 2010-06-23 Universitätsspital Basel Immunoliposomes for treatment of cancer
NZ586123A (en) 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
JP2011506343A (ja) 2007-12-07 2011-03-03 バイパー サイエンシズ，インコーポレイティド トポイソメラーゼ阻害剤とｐａｒｐ阻害剤との組み合わせによるがんの治療
EP2259797A2 (en) 2008-03-25 2010-12-15 Schering Corporation Methods for treating or preventing colorectal cancer
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
US20100022444A1 (en) * 2008-07-24 2010-01-28 Bodybio, Inc. Combination therapy for modulation of activity and development of cells and tissues
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
JP2012525371A (ja) 2009-05-01 2012-10-22 オンコザイム・ファーマ・インコーポレイテッド 癌を治療するためのペンタミジンの組み合わせ
HRP20150911T1 (hr) 2009-12-03 2015-10-23 Jiangsu Hengrui Medicine Co., Ltd. Liposom irinotekana ili njegovog hidroklorida te postupak njegove pripreme
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
MX2013000779A (es) 2010-07-19 2013-07-05 Bipar Sciences Inc Metodos para tratar cancer de mama utilizando 4-yodo-3-nitrobenzamida en combinacion con agentes antitumorales.
CN106432495A (zh) 2010-07-22 2017-02-22 加利福尼亚大学董事会 抗肿瘤抗原抗体及其使用方法
RU2541100C2 (ru) * 2010-09-03 2015-02-10 Боард Оф Регентс Оф Зе Юниверсити Оф Небраска Способ и композиция для лечения рака
AU2011338487B2 (en) 2010-12-06 2016-12-22 Merrimack Pharmaceuticals, Inc. Dosage and administration for preventing cardiotoxicity in treatment with ErbB2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
CA2821024A1 (en) 2010-12-14 2012-06-21 Technical University Of Denmark Entrapment of radionuclides in nanoparticle compositions
JP6054308B2 (ja) 2011-02-15 2016-12-27 メリマック ファーマシューティカルズ， インコーポレイテッドＭｅｒｒｉｍａｃｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 核酸を細胞へ送達する組成物及び方法
JP5588086B2 (ja) 2011-04-19 2014-09-10 メリマック ファーマシューティカルズ インコーポレーティッド 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
JP6245481B2 (ja) 2012-04-17 2017-12-13 メリマック ファーマシューティカルズ インコーポレーティッド 非侵襲的イメージングのための組成物および方法
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
AU2013374248A1 (en) 2012-12-14 2015-06-11 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
PL2979700T3 (pl) 2013-03-27 2019-03-29 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy zawierający małą dawkę hydratu chlorowodorku irynotekanu
US10111871B2 (en) 2013-08-27 2018-10-30 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
US20160303264A1 (en) 2013-10-23 2016-10-20 Merrimack Pharmaceuticals, Inc. Liposomes useful for non-invasive imaging and drug delivery
AU2015360761B2 (en) 2014-12-09 2021-05-20 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
TW201701880A (zh) 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
AU2016309002B2 (en) 2015-08-20 2021-07-29 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment
HK1257220A1 (zh) * 2015-08-21 2019-10-18 益普生生物制药有限公司 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法
RS67289B1 (sr) 2015-10-16 2025-11-28 Ipsen Biopharm Ltd Stabilizacija farmaceutskih kompozicija kamptotecina
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
SG11201809788VA (en) 2016-05-18 2018-12-28 Ipsen Biopharm Ltd Nanoliposomal irinotecan for use in treating small cell lung cancer
CN106420789A (zh) * 2016-10-08 2017-02-22 中国人民解放军总医院 复发耐药消化道肿瘤地西他滨综合治疗方案
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BMC Cancer, 12:199 pp.1-7(2012) 1부.*
The New England Journal of Medicine, 364(19), pp.1817-1825(2011) 1부.*

Also Published As

Publication number Publication date
HK1257250A1 (en) 2019-10-18
AU2016310476B8 (en) 2021-10-07
EP3791876A1 (en) 2021-03-17
NZ739464A (en) 2024-11-29
HK1257220A1 (zh) 2019-10-18
RU2018105666A (ru) 2019-09-23
PT3337478T (pt) 2020-10-19
RU2747124C2 (ru) 2021-04-28
BR112018002941B1 (pt) 2023-12-05
CN108495629A (zh) 2018-09-04
IL257149B1 (en) 2024-07-01
AU2016310476A1 (en) 2018-02-22
IL257149A (en) 2018-03-29
MX385425B (es) 2025-03-18
CA2993451A1 (en) 2017-03-02
TW201717933A (zh) 2017-06-01
KR20180039087A (ko) 2018-04-17
US20230062425A1 (en) 2023-03-02
EP3337478B1 (en) 2020-08-12
TW202508602A (zh) 2025-03-01
US20240358706A1 (en) 2024-10-31
SI3337478T1 (sl) 2020-10-30
IL257149B2 (en) 2024-11-01
US20170049775A1 (en) 2017-02-23
TW202126293A (zh) 2021-07-16
EP3337478A1 (en) 2018-06-27
BR112018002941A2 (pt) 2018-11-27
JP7463329B2 (ja) 2024-04-08
RU2018105666A3 (cg-RX-API-DMAC7.html) 2020-02-21
AU2016310476B2 (en) 2021-09-30
JP2018528185A (ja) 2018-09-27
US11344552B2 (en) 2022-05-31
US20250381191A1 (en) 2025-12-18
MX2018001802A (es) 2018-05-16
JP2024045587A (ja) 2024-04-02
TW202400181A (zh) 2024-01-01
TWI778942B (zh) 2022-10-01
WO2017034957A1 (en) 2017-03-02
US20180078556A1 (en) 2018-03-22
TW202243677A (zh) 2022-11-16
JP2022009657A (ja) 2022-01-14
ES2826826T3 (es) 2021-05-19
SG10201913077QA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
KR102714060B1 (ko) 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법
RU2761953C2 (ru) Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
CA2993451C (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
HK40045473A (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
HK1257250B (en) Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer
HK40009222A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210818

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240112

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240702

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240930

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241002

End annual number: 3

Start annual number: 1

PG1601 Publication of registration